Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurochem ; 95(1): 33-45, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16045451

RESUMO

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by a prominent loss of GABA-ergic medium-sized spiny neurons in the caudate putamen. There is evidence that impaired energy metabolism contributes to neuronal death in HD. Creatine is an endogenous substrate for creatine kinases and thereby supports cellular ATP levels. This study investigated the effects of creatine supplementation (5 mm) on cell survival and neuronal differentiation in striatal cultures. Chronic creatine treatment resulted in significant increased densities of GABA-immunoreactive (-ir) neurons, although total neuronal cell number and general viability were not affected. Similar effects were seen after short-term treatment, suggesting that creatine acted as a differentiation factor. Inhibitors of transcription or translation did not abolish the creatine-mediated effects, nor did omission of extracellular calcium, whereas inhibition of mitogen-activated protein kinase and phosphatidylinositol-3-kinase significantly attenuated the creatine induced increase in GABA-ir cell densities. Creatine exhibited significant neuroprotection against toxicity instigated either by glucose- and serum deprivation or addition of 3-nitropropionic acid. In sum, the neuroprotective properties in combination with promotion of neuronal differentiation suggest that creatine has potential as a therapeutic drug in the treatment of neurodegenerative diseases, like HD.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Corpo Estriado/citologia , Corpo Estriado/metabolismo , Creatina/farmacologia , Neurônios/citologia , Neurônios/metabolismo , Ácido gama-Aminobutírico/metabolismo , Animais , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Creatina/administração & dosagem , Creatina Quinase/metabolismo , Meios de Cultura Livres de Soro/farmacologia , Relação Dose-Resposta a Droga , Esquema de Medicação , Glucose/deficiência , Isoenzimas/metabolismo , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Neurotoxinas/farmacologia , Nitrocompostos , Fosfatidilinositol 3-Quinases/metabolismo , Propionatos/farmacologia , Ratos , Ratos Wistar , Células-Tronco/citologia , Células-Tronco/metabolismo , Distribuição Tecidual
2.
Neuroscience ; 133(3): 701-13, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15890457

RESUMO

Parkinson's disease is a disabling neurodegenerative disorder of unknown etiology characterized by a predominant and progressive loss of dopaminergic neurons in the substantia nigra. Recent findings suggest that impaired energy metabolism plays an important role in the pathogenesis of this disorder. The endogenously occurring guanidino compound creatine is a substrate for mitochondrial and cytosolic creatine kinases. Creatine supplementation improves the function of the creatine kinase/phosphocreatine system by increasing cellular creatine and phosphocreatine levels and the rate of ATP resynthesis. In addition, mitochondrial creatine kinase together with high cytoplasmic creatine levels inhibit mitochondrial permeability transition, a major step in early apoptosis. In the present study, we analyzed the effects of externally added creatine on the survival and morphology of dopaminergic neurons and also addressed its neuroprotective properties in primary cultures of E14 rat ventral mesencephalon. Chronic administration of creatine [5 mM] for 7 days significantly increased survival (by 1.32-fold) and soma size (by 1.12-fold) of dopaminergic neurons, while having no effect on other investigated morphological parameters. Most importantly, concurrent creatine exerted significant neuroprotection for dopaminergic neurons against neurotoxic insults induced by serum and glucose deprivation (P < 0.01), 1-methyl-4-phenyl pyridinium ion (MPP+) [15 microM] and 6-hydroxydopamine (6-OHDA) [90 microM] exposure (P < 0.01). In addition, creatine treatment significantly protected dopaminergic cells facing MPP+-induced deterioration of neuronal morphology including overall process length/neuron (by 60%), number of branching points/neuron (by 80%) and area of influence per individual neuron (by 60%). Less pronounced effects on overall process length/neuron and number of branching points/neuron were also found after 6-OHDA exposure (P < 0.05) and serum/glucose deprivation (P < 0.05). In conclusion, our findings identify creatine as a rather potent natural survival- and neuroprotective factor for developing nigral dopaminergic neurons, which is of relevance for therapeutic approaches in Parkinson's disease and for the improvement of cell replacement strategies.


Assuntos
Creatina/farmacologia , Dopamina/fisiologia , Mesencéfalo/citologia , Neurônios/citologia , Neurônios/efeitos dos fármacos , 1-Metil-4-fenilpiridínio/farmacologia , Animais , Forma Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Creatina Quinase/metabolismo , Creatina Quinase Forma BB , Creatina Quinase Mitocondrial , Creatinina/metabolismo , Interações Medicamentosas , Feminino , Isoenzimas/metabolismo , Neurônios/metabolismo , Oxidopamina/farmacologia , Gravidez , Ratos , Ratos Sprague-Dawley , Simpatolíticos/farmacologia , Tirosina 3-Mono-Oxigenase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...